NeuBase Therapeutics, Inc.
NBSEDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted in 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q1 2024
Institutional positions in NeuBase Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
NBSE is no longer listed, so this page shows Q1 2024. 13F filings for later quarters list far fewer holders.
- Institutional holders
- 18
- −2 vs. Q4 2023
- Shares held
- 393.4K
- +69.5K (+21.5%) vs. Q4 2023
- Total value
- $177.1K
- −$62.2K (−26.0%) vs. Q4 2023
- New holders
- 2
- 2 more added
- Sold out
- 4
- 2 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NBSE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 2 | $4.95K |
| Q1 2024 | 18 | $177.1K |
| Q4 2023 | 21 | $340.2K |
| Q3 2023 | 20 | $301.2K |
| Q2 2023 | 26 | $1.08M |
| Q1 2023 | 36 | $1.72M |
| Q4 2022 | 35 | $1.94M |
| Q3 2022 | 44 | $4.74M |
| Q2 2022 | 43 | $13.4M |
| Q1 2022 | 45 | $23.3M |
| Q4 2021 | 46 | $31.7M |
| Q3 2021 | 48 | $36.6M |
| Q2 2021 | 59 | $51.5M |
| Q1 2021 | 57 | $59.4M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding NeuBase Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| DME Capital Management, LPSuperinvestorGreenlight Capital | 136,350 | $61.3K | 0.00% | +136,350 | New |
| Renaissance Technologies LLC | 88,229 | $40.0K | 0.00% | +31,262+54.9% | Added |
| Point72 Asset Management, L.P. | 62,500 | $28.1K | 0.00% | 00.0% | Unchanged |
| Carnegie Mellon University | 46,970 | $21.1K | 0.03% | 00.0% | Unchanged |
| Vanguard Group Inc | 18,981 | $8.54K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 15,550 | $7.00K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 15,482 | $6.84K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 4,056 | $1.82K | 0.00% | −61,668−93.8% | Reduced |
| Tower Research Capital LLC (TRC) | 2,572 | $1.16K | 0.00% | +124+5.1% | Added |
| Cubist Systematic Strategies, LLC | 1,251 | $563 | 0.00% | +1,251 | New |
| Bank of America Corp | 804 | $361 | 0.00% | 00.0% | Unchanged |
| First Manhattan Co | 353 | $158 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 79 | $35 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 22 | $10 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 21 | $9 | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 12 | $5 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 9 | $4 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 153 | $0 | 0.00% | −147−49.0% | Reduced |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −21,083−100.0% | Sold out |
| Kestra Advisory Services, LLC | 0 | $0 | 0.00% | −16,476−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −84−100.0% | Sold out |
| Global Wealth Management Investment Advisory, Inc. | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Greenlight Capital Inc | – | – | – | – | Not filed |